In This Article:
The German stock market has recently shown resilience, with the DAX gaining 0.35% despite broader volatility and economic uncertainties in Europe. Amid these fluctuations, identifying undervalued stocks can offer a strategic advantage for investors looking to capitalize on potential market inefficiencies. In this context, finding stocks that are trading below their intrinsic value becomes crucial. Such opportunities often arise from temporary market dislocations or overlooked fundamentals, making them attractive options for those seeking long-term growth in a turbulent environment.
Top 10 Undervalued Stocks Based On Cash Flows In Germany
Name | Current Price | Fair Value (Est) | Discount (Est) |
Bertrandt (XTRA:BDT) | €24.00 | €42.41 | 43.4% |
Gerresheimer (XTRA:GXI) | €96.65 | €190.80 | 49.3% |
technotrans (XTRA:TTR1) | €16.70 | €32.72 | 49% |
M1 Kliniken (XTRA:M12) | €14.20 | €23.69 | 40.1% |
ecotel communication ag (XTRA:E4C) | €13.80 | €21.95 | 37.1% |
Verbio (XTRA:VBK) | €16.40 | €29.78 | 44.9% |
RENK Group (DB:R3NK) | €25.64 | €43.02 | 40.4% |
MTU Aero Engines (XTRA:MTX) | €265.30 | €493.63 | 46.3% |
Dr. Hönle (XTRA:HNL) | €16.95 | €28.94 | 41.4% |
Vectron Systems (XTRA:V3S) | €11.10 | €17.58 | 36.8% |
Let's review some notable picks from our screened stocks.
adidas
Overview: adidas AG, with a market cap of €38.78 billion, designs, develops, produces, and markets athletic and sports lifestyle products across Europe, the Middle East, Africa, North America, Greater China, the Asia-Pacific region, and Latin America.
Operations: adidas generates revenue from several regions: €3.26 billion in Greater China, €2.39 billion in Latin America, and €5.07 billion in North America.
Estimated Discount To Fair Value: 22.8%
adidas AG, trading 22.8% below its estimated fair value, reported strong Q2 2024 results with net income rising to €190 million from €84 million a year ago. The company revised its full-year guidance upwards, now expecting operating profit around €1 billion. Despite unfavorable currency effects impacting profitability, adidas's earnings are forecast to grow significantly at 40.7% annually over the next three years, outpacing the German market's growth rate of 19.7%.
-
Insights from our recent growth report point to a promising forecast for adidas' business outlook.
-
Dive into the specifics of adidas here with our thorough financial health report.
Formycon
Overview: Formycon AG is a biotechnology company that develops biosimilar drugs in Germany and Switzerland, with a market cap of €878.59 million.
Operations: Revenue Segments (in millions of €): null